Halozyme Therapeutics (HALO) Projected to Post Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect Halozyme Therapeutics to post earnings of $0.98 per share and revenue of $231.21 million for the quarter.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, analysts expect Halozyme Therapeutics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Halozyme Therapeutics Stock Up 1.9 %

NASDAQ:HALO traded up $1.16 during trading hours on Friday, reaching $61.19. The company's stock had a trading volume of 1,098,414 shares, compared to its average volume of 1,443,747. Halozyme Therapeutics has a one year low of $40.19 and a one year high of $66.00. The business's 50-day moving average is $60.79 and its 200-day moving average is $55.41. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The company has a market cap of $7.56 billion, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock worth $1,558,052 in the last ninety days. 2.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HALO shares. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.